IDH1 and central nervous system cancer: reported that a subgroup of glioma patients with tumors harboring the isocitrate dehydrogase 1 (IDH1) mutation, which leads to the production of D‐2‐hydroxyglutarate (D‐2‐HG), are at very low risk of VTE 7.